- Book学术

发布求助

文献互助智能选刊最新文献

Q2 Pharmacology, Toxicology and Pharmaceutics

Drugs in Context Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI:10.7573/dic.2024-10-5

Carlos Escobar, Jesús Saldaña, José Luis Merino, Rafael Peinado

{"title":"Vericiguat in patients with heart failure and implantable cardioverter-defibrillator.","authors":"Carlos Escobar, Jesús Saldaña, José Luis Merino, Rafael Peinado","doi":"10.7573/dic.2024-10-5","DOIUrl":null,"url":null,"abstract":"Background: This analysis assesses the effectiveness and tolerability profile of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.Methods: Retrospective analysis of patients with HFrEF and implantable cardioverter-defibrillator who started treatment with vericiguat in daily clinical practice in a tertiary university hospital in Spain.Results: The study population comprised 14 patients treated since January 2023. At baseline, mean age was 77.0±7.0 years, 71.4% of patients were men and mean left ventricular ejection fraction was 32.1±5.4%. Regarding heart failure treatments, 13 (92.3%) patients were prescribed renin-angiotensin-aldosterone system inhibitors, mainly sacubitril-valsartan (61.5%), they were all prescribed aldosterone antagonists, 10 (71.4%) were prescribed β-blockers and 10 (71.4%) were prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors. After a mean duration of treatment with vericiguat of 12.4±5.3 months, two (14.3%) patients presented to the emergency department, one with hypotension and the other with impaired kidney function, and a further two (14.3%) patients were hospitalised, one of whom had decompensated heart failure. At baseline, four (28.6%) patients presented non-sustained/sustained ventricular tachycardia; at study end, this decreased to two patients (50% of patients with ventricular arrhythmias at baseline). Additionally, in one patient (25% of patients with ventricular arrhythmias at baseline), there was a substantial reduction in the number of episodes of ventricular arrhythmia. At study end, seven patients achieved the target dose of 10 mg daily and one patient discontinued vericiguat owing to hypotension.Conclusions: Amongst patients with HFrEF and implantable cardioverter-defibrillator, vericiguat showed a good safety profile in addition to standard heart failure therapy, with low rates of adverse events. Moreover, a potential reduction in the risk of ventricular arrhythmias could also be obtained with vericiguat.","PeriodicalId":11362,"journal":{"name":"Drugs in Context","volume":"14 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11900887/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in Context","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7573/dic.2024-10-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

背景：本分析评估了韦立克对射血分数降低型心力衰竭（HFrEF）和植入式心律转复除颤器患者的有效性和耐受性，重点关注室性心律失常的出现：方法：对西班牙一家三级大学医院在日常临床实践中开始使用韦立克治疗的 HFrEF 和植入式心律转复除颤器患者进行回顾性分析：研究对象包括自2023年1月起接受治疗的14名患者。基线平均年龄为（77.0±7.0）岁，71.4%的患者为男性，平均左室射血分数为（32.1±5.4）%。在心衰治疗方面，13 名（92.3%）患者接受了肾素-血管紧张素-醛固酮系统抑制剂治疗，主要是沙库比曲-缬沙坦（61.5%），他们都接受了醛固酮拮抗剂治疗，10 名（71.4%）患者接受了β受体阻滞剂治疗，10 名（71.4%）患者接受了钠-葡萄糖共转运体-2（SGLT2）抑制剂治疗。韦立克治疗的平均持续时间为（12.4±5.3）个月，其中两名（14.3%）患者到急诊科就诊，一名患者出现低血压，另一名患者肾功能受损，另有两名（14.3%）患者住院治疗，其中一名患者出现失代偿性心力衰竭。基线时，有四名患者（28.6%）出现非持续性/持续性室性心动过速；研究结束时，这一比例降至两名患者（占基线时室性心律失常患者的 50%）。此外，一名患者（占基线室性心律失常患者的 25%）的室性心律失常发作次数大幅减少。研究结束时，7名患者达到了每天10毫克的目标剂量，1名患者因低血压停用了维力古特：结论：在使用植入式心律转复除颤器的高心衰患者中，除标准心衰治疗外，维力古特还具有良好的安全性，不良反应发生率较低。此外，维力古特还能降低室性心律失常的潜在风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Vericiguat in patients with heart failure and implantable cardioverter-defibrillator.

Background: This analysis assesses the effectiveness and tolerability profile of vericiguat in patients with heart failure with reduced ejection fraction (HFrEF) and implantable cardioverter-defibrillator, with an emphasis on the emergence of ventricular arrhythmias.

Methods: Retrospective analysis of patients with HFrEF and implantable cardioverter-defibrillator who started treatment with vericiguat in daily clinical practice in a tertiary university hospital in Spain.

Results: The study population comprised 14 patients treated since January 2023. At baseline, mean age was 77.0±7.0 years, 71.4% of patients were men and mean left ventricular ejection fraction was 32.1±5.4%. Regarding heart failure treatments, 13 (92.3%) patients were prescribed renin-angiotensin-aldosterone system inhibitors, mainly sacubitril-valsartan (61.5%), they were all prescribed aldosterone antagonists, 10 (71.4%) were prescribed β-blockers and 10 (71.4%) were prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors. After a mean duration of treatment with vericiguat of 12.4±5.3 months, two (14.3%) patients presented to the emergency department, one with hypotension and the other with impaired kidney function, and a further two (14.3%) patients were hospitalised, one of whom had decompensated heart failure. At baseline, four (28.6%) patients presented non-sustained/sustained ventricular tachycardia; at study end, this decreased to two patients (50% of patients with ventricular arrhythmias at baseline). Additionally, in one patient (25% of patients with ventricular arrhythmias at baseline), there was a substantial reduction in the number of episodes of ventricular arrhythmia. At study end, seven patients achieved the target dose of 10 mg daily and one patient discontinued vericiguat owing to hypotension.

Conclusions: Amongst patients with HFrEF and implantable cardioverter-defibrillator, vericiguat showed a good safety profile in addition to standard heart failure therapy, with low rates of adverse events. Moreover, a potential reduction in the risk of ventricular arrhythmias could also be obtained with vericiguat.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Drugs in Context Medicine-Medicine (all)

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Covers all phases of original research: laboratory, animal and human/clinical studies, health economics and outcomes research, and postmarketing studies. Original research that shows positive or negative results are welcomed. Invited review articles may cover single-drug reviews, drug class reviews, latest advances in drug therapy, therapeutic-area reviews, place-in-therapy reviews, new pathways and classes of drugs. In addition, systematic reviews and meta-analyses are welcomed and may be published as original research if performed per accepted guidelines. Editorials of key topics and issues in drugs and therapeutics are welcomed. The Editor-in-Chief will also consider manuscripts of interest in areas such as technologies that support diagnosis, assessment and treatment. EQUATOR Network reporting guidelines should be followed for each article type. GPP3 Guidelines should be followed for any industry-sponsored manuscripts. Other Editorial sections may include Editorial, Case Report, Conference Report, Letter-to-the-Editor, Educational Section.